Hims & Hers (HIMS) Health is offering lab testing and sees the business as a $1B opportunity, Kelly Cloonan of Wall Street Journal reports. “You know, size of this market is, I think every single person in the country,” Hims Chief Executive Andrew Dudum told the Journal. He expects the offering to eventually represent a $1B business, Cloonan adds. Hims customers will access testing at Quest Diagnostics’ (DGX), then receive results and consult with providers on the platform for a personalized plan that could include prescriptions, supplements or nutrition guidance, Dudum said.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers Health Faces Declining User Engagement and Growth Challenges Amid Industry Pressures
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China
- GLP-1 price cuts limit Hims advantage, says Needham
- Sell Recommendation for Hims & Hers Health Amid Competitive Pricing Pressures and Projected Decline
- TrumpRx GLP-1 pricing ‘less bad than feared’ for Hims & Hers, says Citi